{"id":373,"date":"2021-12-03T22:28:19","date_gmt":"2021-12-03T22:28:19","guid":{"rendered":"http:\/\/princetonillinois.com\/?p=373"},"modified":"2021-12-03T22:28:19","modified_gmt":"2021-12-03T22:28:19","slug":"bristol-myers-squibbs-applications-for-deucravacitinib-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-accepted-by-u-s-food-and-drug-administration-and-validated-by-european-medicines","status":"publish","type":"post","link":"https:\/\/princetonillinois.com\/?p=373","title":{"rendered":"Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency – Business Wire"},"content":{"rendered":"

Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency<\/a>  Business Wire<\/font>
source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency  Business Wiresource<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-373","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t